Three UK-Based Hospital Systems Exploring the Power of Paige’s AI for Diagnosing Prostate Cancer in Live Clinical Settings
22 Julio 2024 - 6:00AM
Business Wire
North Bristol Trust NHS Trust, University
Hospitals Coventry and Warwickshire NHS Trust, and Oxford
University NHS Foundation Trust are Evaluating the Paige Prostate
Suite to Explore the Potential To Help Improve Cancer Diagnostics
Across England
In a collaborative project led by the University of Oxford,
Paige, a global leader in clinical AI applications that assist in
diagnosing cancer, today announced that the Articulate Pro study
has achieved live, multisite clinical use study involving three
hospital systems across England: North Bristol Trust Southmead
Hospital, University Hospitals Coventry and Warwickshire, and
Oxford University NHS Foundation Trust. Each hospital uses
different digital pathology scanners and information systems and
serves distinct patient populations —but are all adding Paige’s
powerful artificial intelligence (AI) technology to their standard
of care to determine the potential to improve patient outcomes
against a background of rising instances of prostate cancer.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240722858117/en/
(Photo: Business Wire)
The Paige Prostate Suite is a system of diagnostic AI
applications designed to help pathologists detect, grade and
measure tumours in prostate biopsies and tissue samples.
Pathologists at these three hospital systems are assessing how
Paige Prostate Suite impacts their clinical decision-making,
pathology service delivery, and use of resources in a real-world
setting. With this use across multiple hospitals, pathologists can
assess the ways Paige’s AI technology can best serve patients,
histopathologists, and hospital systems for prostate cancer
diagnosis. This development is the latest achievement of the
ARTICULATE PRO study, funded by the Accelerated Access
Collaborative (AAC) Artificial Intelligence in Health and Care
Award, overseen by the Department of Health and Social Care.
“The central focus of ARTICULATE PRO is patients. We are
striving towards our goal to safely and effectively ensure they
benefit the most from powerful AI technology,” said Professor Clare
Verrill, OUH Cellular Pathology Consultant, Associate Professor and
Principal Investigator of ARTICULATE PRO. “With the multisite live
use of The Paige Prostate Suite, we can systematically study
benefits to patients in clinical settings.”
Dr. Jon Oxley, uropathologist and Bristol lead of ARTICULATE
PRO, added, “I have studied the disease and progression of prostate
cancer in clinical research for over 25 years, it is a significant
advancement that Paige’s AI applications have achieved a level of
validation and performance that allows safe and effective live
clinical use. Using Paige Prostate Suite alongside our standard of
care has the promise to increase efficiency and improve
reproducibility of results for patients.”
Dr. Bidisa Sinha, uropathologist at University Hospitals
Coventry and Warwickshire, agreed, “We believe AI can help to
improve the accuracy and consistency of grading cancer and assist
in detection of small areas of cancer which are easy to miss. This
is world-leading research being carried out at UHCW. We are proud
to be a global leader in the field of digital and computational
pathology.”
About Paige
Paige uses the power of AI to drive a new era of cancer
discovery and treatment. To improve the lives of patients with
cancer, Paige has created a cloud-based platform that transforms
pathologists’ workflow and increases diagnostic confidence as well
as productivity, all on a global scale. Paige is the first company
to receive FDA approval for a clinical AI application in digital
pathology. The same Paige technology empowers pharmaceutical
companies to more effectively evaluate treatment options for
patients and design new biomarkers for drug development so that
every patient gets precise treatment options.
Paige Prostate Detect, which is a component of The Paige
Prostate Suite, remains the first and only FDA approved AI
algorithm for detecting prostate cancer in the U.S. It is also
CE-IVD and UKCA compliant.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722858117/en/
Media Contact: Cindi Goodsell | Stanton Cgoodsell@stantonprm.com
510-409-3646